A5102997364- Forest ecology and management
- Lung Cancer Treatments and Mutations
- Wood Treatment and Properties
- Pediatric health and respiratory diseases
- Colorectal Cancer Treatments and Studies
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Gastrointestinal Tumor Research and Treatment
- Tuberculosis Research and Epidemiology
- Cancer Genomics and Diagnostics
- Gut microbiota and health
- HER2/EGFR in Cancer Research
- Genetic factors in colorectal cancer
- Gastrointestinal disorders and treatments
- Wood and Agarwood Research
- Ecology and Conservation Studies
- Lung Cancer Diagnosis and Treatment
- Spaceflight effects on biology
- Myofascial pain diagnosis and treatment
- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Tree Root and Stability Studies
Mie University
2021-2025
Soka Municipal Hospital
2017
Abstract Background Immune checkpoint inhibitors have recently become the standard of care in first‐line treatment extensive‐stage small cell lung cancer. Although immune‐related adverse events been reported to influence prognosis non‐small cancer patients, few studies investigated prognostic value patients. In this study, we evaluated patients who developed after with immune inhibitor‐based chemotherapy for Methods We enrolled 90 received as from September 2019 December 2022 six hospitals...
Pulmonary enteric adenocarcinoma (PEAC) is an extremely rare subtype of non-small cell lung cancer, characterised by histopathological features that resemble colorectal adenocarcinoma. Here, we report a case PEAC in 85-year-old male who presented with pulmonary nodule initially identified at the age 76. Initial PET-CT (maximum standardised uptake value [SUVmax] = 2.8) was inconclusive, leading to strict follow-up. Over 9 years, enlarged significantly (3.2 cm, SUVmax 8.4). A transbronchial...
Adding an immune checkpoint inhibitor to chemotherapy treat extensive-stage small cell lung cancer is effective. However, there are no reports of effective second-line treatment in patients previously treated with and inhibitors as a first-line treatment. Here, we assessed the efficacy safety amrubicin for after combination therapy. The study enrolled 150 cancer. incidence adverse events were compared between without previous One hundred twenty-three eligible. There was difference objective...